One of the best anti-aging products you can find without a prescription doesn’t come in a fancy jar or cost hundreds of dollars. In fact, it’s not even best known for its incredible anti-aging effects ...

Differin Gel 0.1% has been approved for over-the-counter treatment of acne. Differin Gell 0.1% (adapalene) is the first retinoid approved for over-the-counter treatment of acne by the FDA. The FDA has ...

Lausanne, Switzerland – July 16, 2008 – Galderma Pharma S.A., a global specialty pharmaceutical company focused on dermatology, announced today that Japan's Ministry of Health, Labor and Welfare has ...

Good news for acne sufferers: The U.S. Food and Drug Administration has approved an over-the-counter retinoid drug for acne -- the first new active ingredient available without a prescription since ...

The Nonprescription Drugs Advisory Committee of the US Food and Drug Administration (FDA) voted unanimously April 15 to recommend over-the-counter marketing (OTC) of adapalene gel 0.1% (Differin Gel, ...

(HealthDay)—The once-daily acne treatment Differin Gel 0.1% (adapalene) has been approved for over-the counter use among people 12 and older, the U.S. Food and Drug Administration said. It's the first ...

Adapalene 0.1%; alcohol-free. Discontinue if allergic reaction occurs or no improvement after 3 months. Do not use on cuts, abrasions, eczematous, or sunburned skin. Avoid eyes, lips, mouth, sun, UV ...

The Food and Drug Administration (FDA) has approved Differin Gel (adapalene; Galderma) 0.1% for over-the-counter (OTC) treatment for acne in patients aged ≥12 years. The Food and Drug Administration ...

Galderma markets two adapalene cream products: DIFFERIN (0.1% adapalene) and DIFFERIN XP (0.3% adapalene). In 2016, PMPRB staff alleged that Galderma had failed to provide information regarding ...

Galderma Laboratories Release: FDA Approves Differin Gel, 0.3% for Acne FORT WORTH, Texas, June 20 -- Galderma Laboratories, L.P., announced today that the U.S. Food and Drug Administration (FDA) has ...

On December 3, 2024, the Federal Court of Appeal (FCA) set aside the order of the Patented Medicine Prices Review Board (PMPRB or Board) that had required Galderma to continue to provide information ...